Cargando…

Real-World Adverse Effects of Capecitabine Toxicity in an Elderly Population

BACKGROUND: Few studies have assessed the safety and effectiveness of the numerous available chemotherapeutic therapies for geriatric oncology patients. Most safety studies are conducted in large trials, and there is some uncertainty surrounding whether the results would be the same in typical daily...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Beek, Michiel W. H., Roukens, Monique, Jacobs, Wilco C. H., Timmer-Bonte, Johanna N. H., Kramers, Cees
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119165/ https://www.ncbi.nlm.nih.gov/pubmed/29934933 http://dx.doi.org/10.1007/s40801-018-0138-9

Ejemplares similares

Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study
por: Leicher, Laura W., et al.
Publicado: (2016)

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
por: Teimouri, Arezou, et al.
Publicado: (2022)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Hypokalemia secondary to capecitabine: a hidden toxicity?
por: Saif, Muhammad Wasif, et al.
Publicado: (2007)

Development of phimosis as an adverse drug reaction to capecitabine with irinotecan
por: Patel, Priyeshkumar, et al.
Publicado: (2022)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction
por: Baird, R, et al.
Publicado: (2011)

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
por: Peng, Jingyuan, et al.
Publicado: (2018)

Compound mucocutaneous adverse effects of oral capecitabine in a patient
por: Pinto, Hyacinth Peter, et al.
Publicado: (2014)

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)
por: Louie, S G, et al.
Publicado: (2013)

Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
por: Gui, Xinyu, et al.
Publicado: (2020)

A Study of the S-1 or Capecitabine as First-line Regimen in Patients with Metastatic Colorectal Cancer: A Real World Study
por: Guo, Yanan, et al.
Publicado: (2020)

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine
por: de Man, Femke M., et al.
Publicado: (2019)

Genetic Polymorphisms of Dihydropyrimidinase in a Japanese Patient with Capecitabine-Induced Toxicity
por: Hiratsuka, Masahiro, et al.
Publicado: (2015)

New advances in DPYD genotype and risk of severe toxicity under capecitabine
por: Etienne-Grimaldi, Marie-Christine, et al.
Publicado: (2017)

Racial and ethnic differences in capecitabine toxicity in patients with gastrointestinal tract cancers
por: Brazelton, Alicia, et al.
Publicado: (2022)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
por: Gürgöze, Muhammed T., et al.
Publicado: (2018)

Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients
por: Jung, Yun Hwa, et al.
Publicado: (2017)

Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity
por: Ma, Wen Wee, et al.
Publicado: (2016)

Phase I pharmacological study of continuous chronomodulated capecitabine treatment
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis
por: Jacobs, Bart A.W., et al.
Publicado: (2019)

Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports
por: Brickell, K, et al.
Publicado: (2003)

Co-delivery of Cisplatin(IV) and Capecitabine as an Effective and Non-toxic Cancer Treatment
por: Xiao, Xiao, et al.
Publicado: (2019)

Cardiovascular Toxicity of Carfilzomib: The Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States
por: Zhai, Yinghong, et al.
Publicado: (2021)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study
por: Bi, Pingping, et al.
Publicado: (2023)

Use of capecitabine in management of early colon cancer
por: Hameed, H, et al.
Publicado: (2011)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Designing Adverse Event Forms for Real-World Reporting: Participatory Research in Uganda
por: Davies, Emma C., et al.
Publicado: (2012)

Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer
por: García-González, Xandra, et al.
Publicado: (2015)

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens
por: Hansen, Ryan N, et al.
Publicado: (2014)

A Case of Pneumatosis Intestinalis With Pneumoperitoneum as a Potential Delayed Adverse Effect of Capecitabine
por: Khan, Taimoor, et al.
Publicado: (2019)

Hematological toxicities in PARP inhibitors: A real‐world study using FDA adverse event reporting system (FAERS) database
por: Shu, Yamin, et al.
Publicado: (2022)

Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine
por: Vitello, Stefano, et al.
Publicado: (2020)

Expression of Concern: Genetic Polymorphisms of Dihydropyrimidinase in a Japanese Patient with Capecitabine-Induced Toxicity
Publicado: (2023)

Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2011)

Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
por: Molina-Garrido, M J, et al.
Publicado: (2011)

Do Hearing Aids Address Real-World Hearing Difficulties for Adults With Mild Hearing Impairment? Results From a Pilot Study Using Ecological Momentary Assessment
por: Timmer, Barbra H. B., et al.
Publicado: (2018)

Capecitabine-induced Leukoencephalopathy
por: Yoshimura, Kenji, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4b3v4b02n4ln8782ch7sjt5lh6